Molecular Genomics Core

项目摘要 分子基因组学核心（MGC）的总体目标是促进莫菲特癌症中心的研究 (MCC)通过提供高质量的基因组学服务，这是最先进的，及时的，有竞争力的价格。 MGC有三个具体目标，分别是教育、咨询和服务。MGC的可持续性 该模式的基础是促进基因组学技术方面的教育，从而培养人们对基因组学应用的兴趣 来回答具体的科学问题然后，MGC为成员提供免费咨询， 设计和支持赠款申请。这些组成部分导致资助赠款申请进一步推动 需求MGC有三个目标：1）为成员提供具体的实验设计咨询; 2） 为会员提供高质量的分子基因组学服务; 3）为会员提供高质量的基因组学教育。 MGC由六名全职员工组成，提供以下服务： 测序，mRNA和小RNA-Seq，ChIP-seq，定量PCR，桑格测序，细胞系 NanoString nCounter分析和微阵列服务，包括表达、单核苷酸 使用各种平台，使用多态性（SNP）、拷贝数变体（CNV）和甲基化阵列来分析。 MGC通过开发和向成员提供尖端服务，对MCC产生重大影响， 专注于促进精准医疗，使患者受益。MGC与TC和CIC密切合作 提供样品采集、数据生成和分析的无缝集成。MGC的影响是 例如，MGC支持的包括临床和分子数据的顶级出版物的数量， 比如Koomen博士的免疫球蛋白可变区大规模平行测序的新方法 在多发性骨髓瘤患者中（Remily-Wood，2014）和Eric Padron博士对慢性骨髓瘤的描述 在分子水平上的骨髓单核细胞白血病队列（Padron，2014）。 为回应上次的检讨，澳门总督府对其目标进行了重大调整，以改善服务 为成员，并纳入新的技术，如靶向和外显子组测序，RNA-和ChIP- Seq、NanoString和细胞系认证。因此，MGC的收入比过去增长了293% 资助周期，MGC被所有五个项目的成员大量使用。在最近的财政年度， 2009年，MGC为64个MCC成员提供服务，其中88%的总利用率由同行评审资助的成员提供。

PROJECT SUMMARY The overall goal of the Molecular Genomics Core (MGC) is to facilitate research at the Moffitt Cancer Center (MCC) by providing high-quality genomics services that are state-of-the-art, timely, and competitively priced. The MGC has three specific aims centered on education, consultations, and services. MGC's sustainability model is based on promoting education in technological aspects of genomics, which builds interest in their use to answer specific scientific questions. The MGC then offers members free consultations to refine experimental design and to support grant applications. These components lead to funded grant applications further driving demand. The MGC has three aims, to provide: 1) specific experimental design consultations to members; 2) high-quality molecular genomics services to members; and 3) high-quality genomics education to members. The MGC comprises six full-time staff and provides the following services: whole exome and targeted DNA sequencing, mRNA and small RNA-Seq, ChIP-seq, quantitative PCR, Sanger sequencing, cell line authentication, NanoString nCounter analysis, and microarray services including expression, single nucleotide polymorphisms (SNPs), copy number variants (CNV), and methylation arrays using a variety of platforms. The MGC has a major impact on the MCC by developing and providing cutting-edge services to members with a focus on facilitating precision medicine to benefit patients. The MGC works closely with the TC and the CIC to provide seamless integration of sample acquisition, data generation, and analysis. The impact of the MGC is exemplified by the number of MGC-supported top-tier publications that include clinical and molecular data, such as Dr. Koomen's novel approach of massively parallel sequencing of the immunoglobulin variable regions in multiple myeloma patients (Remily-Wood, 2014) and Dr. Eric Padron's characterization of a chronic myelomonocytic leukemia cohort at the molecular level (Padron, 2014). In response to the prior review, the MGC underwent a significant realignment of its aims to improve services for members and to incorporate new technologies such as targeted and exome sequencing, RNA- and ChIP- Seq, NanoString and cell line authentication. As a result, MGC revenues increased by 293% over the past funding cycle, and the MGC is heavily used by members from all five programs. During the most recent fiscal year, the MGC served 64 MCC members, with 88% of total utilization by peer-review-funded members.